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Eﬃ  cacy and safety of very early mobilisation within 24 h of 
stroke onset (AVERT): a randomised controlled trial
The AVERT Trial Collaboration group*
Summary
Background Early mobilisation after stroke is thought to contribute to the eﬀ ects of stroke-unit care; however, the 
intervention is poorly deﬁ ned and not underpinned by strong evidence. We aimed to compare the eﬀ ectiveness of 
frequent, higher dose, very early mobilisation with usual care after stroke.
Methods We did this parallel-group, single-blind, randomised controlled trial at 56 acute stroke units in ﬁ ve countries. 
Patients (aged ≥18 years) with ischaemic or haemorrhagic stroke, ﬁ rst or recurrent, who met physiological criteria 
were randomly assigned (1:1), via a web-based computer generated block randomisation procedure (block size of six), 
to receive usual stroke-unit care alone or very early mobilisation in addition to usual care. Treatment with recombinant 
tissue plasminogen activator was allowed. Randomisation was stratiﬁ ed by study site and stroke severity. Patients, 
outcome assessors, and investigators involved in trial and data management were masked to treatment allocation. 
The primary outcome was a favourable outcome 3 months after stroke, deﬁ ned as a modiﬁ ed Rankin Scale score of 
0–2. We did analysis on an intention-to-treat basis. The trial is registered with the Australian New Zealand Clinical 
Trials Registry, number ACTRN12606000185561.
Findings Between July 18, 2006, and Oct 16, 2014, we randomly assigned 2104 patients to receive either very early 
mobilisation (n=1054) or usual care (n=1050); 2083 (99%) patients were included in the 3 month follow-up assessment. 
965 (92%) patients were mobilised within 24 h in the very early mobilisation group compared with 623 (59%) patients 
in the usual care group. Fewer patients in the very early mobilisation group had a favourable outcome than those in 
the usual care group (n=480 [46%] vs n=525 [50%]; adjusted odds ratio [OR] 0·73, 95% CI 0·59–0·90; p=0·004). 
88 (8%) patients died in the very early mobilisation group compared with 72 (7%) patients in the usual care group 
(OR 1·34, 95% CI 0·93–1·93, p=0·113). 201 (19%) patients in the very early mobilisation group and 208 (20%) of 
those in the usual care group had a non-fatal serious adverse event, with no reduction in immobility-related 
complications with very early mobilisation.
Interpretation First mobilisation took place within 24 h for most patients in this trial. The higher dose, very early 
mobilisation protocol was associated with a reduction in the odds of a favourable outcome at 3 months. Early 
mobilisation after stroke is recommended in many clinical practice guidelines worldwide, and our ﬁ ndings should 
aﬀ ect clinical practice by reﬁ ning present guidelines; however, clinical recommendations should be informed by 
future analyses of dose–response associations.
Funding National Health and Medical Research Council, Singapore Health, Chest Heart and Stroke Scotland, 
Northern Ireland Chest Heart and Stroke, UK Stroke Association, National Institute of Health Research.
Copyright © Bernhardt et al. Open Access article distributed under the terms of CC BY-NC-ND.
Introduction
Early mobilisation after stroke, comprising out-of-bed 
sitting, standing, and walking, is thought to contribute 
to the powerful eﬀ ect of stroke-unit care1,2 and is 
recommended in many guidelines; however, it is poorly 
deﬁ ned and not underpinned by strong evidence.3 The 
biological rationale underlying the potential for early 
out-of-bed training centres around three arguments: (1) 
that bed rest negatively aﬀ ects the musculoskeletal, 
cardiovascular, respiratory, and immune systems,4 and 
might slow recovery; (2) that immobility-related 
complications are common early after stroke5 at a time 
when patients are very inactive;6 and (3) that there might 
be a narrow window of opportunity for brain plasticity 
and repair,7 and the optimum period for change could be 
early after stroke.8 Prompt start and more episodes of 
out-of-bed activity might therefore improve outcome. 
However, early mobilisation also has a plausible potential 
for harm, particularly within the ﬁ rst 24 h of stroke 
onset.9 Harms could include damage to the ischaemic 
penumbra associated with reduced cerebral blood ﬂ ow 
when the head position is raised,10 or increased blood 
pressure associated with activity that might also worsen 
outcome.11 Out-of-bed activity could also result in 
more falls with injury. Concerns about early start of 
mobilisation appear even more pronounced in the case 
of intracerebral haemorrhage9 and in patients with 
ischaemic stroke treated with thrombolysis. These 
concerns are largely driven by clinical concerns about 
the risk of bleeding in the absence of any clear evidence. 
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This background of clinical uncertainty prompted us to 
plan and undertake the AVERT trial.
The phase 2 study of AVERT provided preliminary 
evidence that very early mobilisation started within 24 h of 
stroke onset and continued frequently thereafter was 
feasible, likely to be safe12 with promising improvements 
in walking recovery,13 and could be cost eﬀ ective.14 In 2009, 
AVERT phase 2 was the only completed mobilisation trial 
in which intervention started within 48 h of stroke onset.15
We did the present study to investigate the relative 
eﬃ  cacy of a protocol intended to start earlier than usual 
care, with frequent out-of-bed activity (very early 
mobilisation), compared with usual care, traditionally 
started later (>24 h), with less frequent and lower intensity 
out-of-bed activity. Our clinical hypotheses were that 
more intensive, early out-of-bed activity would improve 
functional outcome at 3 months, reduce immobility-
related complications, and accelerate walking recovery 
with no increase in neurological complications. We also 
postulated that very early mobilisation would result in an 
improvement in quality of life at 12 months and would 
be cost eﬀ ective. We aimed to undertake this large, 
pragmatic trial in a range of stroke units—small and 
large, urban and regional—with existing clinical staﬀ  as 
the intervention teams. We wanted to recruit a broad 
sample of patients, including those with intracerebral 
haemorrhage and those receiving recombinant tissue 
plasminogen activator, to increase external validity and 
clinical relevance.
Methods
Study design and participants
We did this pragmatic, parallel-group, single-blind, 
multicentre, international, randomised controlled trial at 
56 stroke units in ﬁ ve countries: Australia, New Zealand, 
Malaysia, Singapore, and the UK (England, Scotland, 
Northern Ireland, and Wales). Full details of the study 
rationale, design, and statistical analysis have been 
published elsewhere.16
Eligible patients were aged 18 years or older, had 
conﬁ rmed ﬁ rst (or recurrent) stroke (infarct or 
intracerebral haemorrhage), and were admitted to a 
stroke unit within 24 h of stroke onset. Treatment with 
recombinant tissue plasminogen activator was allowed. 
Exclusion criteria were clinically signiﬁ cant pre-morbid 
levels of disability (modiﬁ ed Rankin Scale score >2), 
early deterioration, direct admission to the intensive-
care unit, documented palliative treatment, immediate 
surgery, another serious medical illness or unstable 
coronary condition, no response to voice, systolic blood 
pressure lower than 110 mm Hg or higher than 
220 mm Hg, oxygen saturation lower than 92% with 
Research in context
Evidence before this study
Early mobilisation after stroke is recommended in many 
clinical practice guidelines worldwide. In our 2015 review of 
30 guidelines, early mobilisation was recommended in 
22 examples, but the timing and prescription of the 
mobilisation intervention is scarcely speciﬁ ed. Early 
mobilisation is most often recommended as a method to 
reduce the risk of post-stroke complications, with subsequent 
improvements in favourable outcome expected. Our early 
Cochrane review identiﬁ ed no evidence of beneﬁ t, but 
included only one small randomised controlled trial (AVERT 
phase 2, n=71). A systematic review and meta-analysis by 
Lynch and colleagues identiﬁ ed three randomised controlled 
trials (n=159) in which a protocol of mobilisation starting 
within 24 h of stroke was compared with usual care. In this 
review, the investigators reported improved, albeit 
non-signiﬁ cant, odds of a favourable outcome with early 
mobilisation (Barthel index odds ratio [OR] 1·20, 95% CI 
–0·77 to 3·18; p=0·23; OR 1·16, 95% CI 0·61–2·18; p=0·66, 
with signiﬁ cant heterogeneity I²=66%). The odds of having 
no complications in the ﬁ rst 3 months after stroke did not 
diﬀ er signiﬁ cantly between groups (OR 0·92, 95% CI 
0·46–1·87, p=0·82). Fewer patients had died by 3 months 
after stroke in the usual care group (n=6) than in the early 
mobilisation group (n=15; OR 2·58, 95% CI 0·98–6·79; 
p=0·06), but this ﬁ nding was not signiﬁ cant. When data on 
deaths from this meta-analysis are combined with data from 
the present trial, with both ﬁ xed-eﬀ ects and random-eﬀ ects 
meta-analysis, the ﬁ ndings are not appreciably changed 
(ﬁ xed-eﬀ ects OR 1·35, 95% CI 0·99–1·83; p=0.06; 
random-eﬀ ects OR 1·61, 0·82–3·14; p=0·17, I²=26%). This 
meta-analysis represents the most recent systematic review 
of the topic.
Added value of this study
Before AVERT, evidence in trials came from three studies 
including 159 patients. We now have more robust evidence 
to inform practice. We believe that the results of AVERT are 
very generalisable. We have also shown that large, 
international, high-quality trials of complex interventions in 
stroke care, trials that are led by physiotherapists and nurses, 
are possible.
Interpretation
Very early mobilisation was associated with a signiﬁ cant 
reduction in the odds of little or no disability at 3 months after 
stroke, with no evidence of accelerated walking recovery; 
however, the number of patients who died or had serious 
adverse events at 3 months after stroke did not diﬀ er 
signiﬁ cantly between groups. Our data show that an early, 
lower dose out-of-bed activity regimen is preferable to very 
early, frequent, higher dose intervention, but clinical 
recommendations should be informed by the future 
prespeciﬁ ed, detailed analysis of the dose–response association.
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oxygen supplementation, resting heart rate of less than 
40 beats per min or more than 110 beats per min, 
temperature greater than 38·5°C, or enrolment in 
another intervention trial. Patients with subarachnoid 
haemorrhage were not eligible for the trial.
Institutional review boards at all sites approved the 
study. Eligible patients were invited to participate in a 
trial testing “diﬀ erent types of rehabilitation”, but were 
given no speciﬁ c information about the two approaches.16 
Informed consent was obtained from all patients or their 
nominated representative.
Randomisation and masking
Patients were randomly assigned (1:1), with a secure, 
remote, web-based computer-generated block random-
isation procedure (block size of six), to receive usual 
stroke-unit care alone or very early mobilisation in 
addition to usual care. Randomisation was stratiﬁ ed by 
study site and stroke severity on the basis of baseline 
National Institutes of Health Stroke Scale (NIHSS) 
score: mild (NIHSS 1–7), moderate (8–16), and severe 
(>16).17 Intervention staﬀ  were masked to treatment 
allocation. To reduce the risk of contamination of usual 
care intervention, staﬀ  were trained to conceal the 
mobilisation protocol and group allocation, patients 
were unaware of their treatment group, and outcome 
assessors and investigators involved in trial and data 
management were masked to group assignment.
Procedures
Components of usual care, including physical therapies, 
were at the discretion of individual sites. The very 
early mobilisation intervention included three crucial 
elements: (1) begin within 24 h of stroke onset; (2) focus 
on sitting, standing, and walking (ie, out-of-bed) activity; 
and (3) result in at least three additional out-of-bed 
sessions to usual care. Patients assigned to very early 
mobilisation were assisted by physiotherapy and nursing 
staﬀ  trained in study procedures to continue out-of-bed 
activity at a dose guided by a detailed intervention 
protocol. The task-speciﬁ c intervention targeted recovery 
of standing and walking. Functional ability dictated 
intervention dose, with four levels speciﬁ ed, and dose was 
adjusted in line with recovery (titrated). We applied a 
strict protocol in the case of a patient’s ﬁ rst time out of 
bed, with mobilisation out of bed only if the patient’s 
blood pressure did not drop by more than 30 mm Hg on 
achievement of an upright position. The intervention 
period lasted 14 days or until discharge from stroke-unit 
care, whichever was sooner. Therapy and nursing input 
in both groups was recorded online. Very early 
mobilisation interventions were not recorded in medical 
records. Throughout the trial, intervention staﬀ  received 
feedback from an external monitor about intervention 
compliance per patient, and received quarterly com-
pliance summaries. These summaries were reviewed 
regularly by the Data Safety and Monitoring Committee.
Outcomes
The primary outcome was a favourable outcome at 
3 months after stroke, measured with the modiﬁ ed 
Rankin Scale.18 The modiﬁ ed Rankin Scale is an ordinal 
scale ranging from 0 (no disability) to 5 (severe disability), 
with a score of 6 allocated to those who die. We deﬁ ned a 
favourable outcome as modiﬁ ed Rankin Scale scores of 
0–2 (no or minimum disability) and a poor outcome as 
scores of 3–6 (moderate or severe disability, or death).
Major secondary outcomes included an assumption-
free ordinal shift19,20 of the modiﬁ ed Rankin score across 
the entire range of the scale; time taken to achieve 
unassisted walking over 50 m and the proportion of 
patients achieving unassisted walking by 3 months; and 
deaths and the number of non-fatal serious adverse 
events at 3 months. All serious adverse events were 
reported according to standard deﬁ nitions. Important 
medical events were events most relevant to the time 
period (acute stroke) and intervention, and included 
stroke progression, recurrent strokes, falls, angina, 
myocardial infarctions, deep-vein thromboses, pulmonary 
emboli, pressure sores, chest infections, urinary tract 
infections, and depression. All deaths and serious adverse 
events were independently adjudicated by an outcome 
committee masked to treatment allocation, including a 
review of source data when necessary. We classiﬁ ed 
complications as immobility related or neurological, and 
examined each class of complication separately. Serious 
Figure 1: Trial proﬁ le
mRS=modiﬁ ed Rankin Scale. *More than one reason possible per patient.
25 237 admitted within 24 h 
of stroke onset
23 133 ineligible*
5588 had premorbid mRS>2
1136 were enrolled in other clinical trials
7080 were medically unstable or unwell
7414 had no recruiter or were admitted 
on a weekend
8151 for other reasons
 446 refused
2104 enrolled
2104 randomised
1050 allocated to usual care
1045 assessed at 3 months
973 alive
 72 dead
5 refused follow-up
14 never mobilised
21 not stroke
1054 allocated to very 
early mobilisation
1038 assessed at 3 months
950 alive
 88 dead
6 unknown
10 refused follow-up
12 never mobilised
13 not stroke
1050 included in 
intention-to-treat 
primary analysis
1054 included in 
intention-to-treat 
primary analysis
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complications were categorised into immobility related 
(pulmonary embolism, deep-vein thrombosis, urinary 
tract infection, pressure sores, and pneumonia) or 
neurological (stroke progression and recurrent stroke). 
Assessments were done in person or, if necessary, by 
telephone by a trained assessor remote from the hospital 
ward and masked to treatment allocation.
Because very early mobilisation was a complex 
intervention, we prespeciﬁ ed exploration of dose and 
subgroup analyses for age, stroke severity, stroke subtype 
(infarct or haemorrhage), treatment with recombinant 
tissue plasminogen activator, and time to mobilisation 
on 3 month outcome.
Statistical analysis
We powered the study to detect an absolute risk reduction 
of a poor outcome of 7·1% or greater, on the basis of 
two rationales: (1) consensus among investigators and 
international advisers that an absolute risk reduction of 
this magnitude would represent a clinically meaningful 
eﬀ ect size; and (2) 3 month data for death and 
institutionalisation from a hospital that has practised 
early mobilisation for many years showing 9·1% better 
outcome than in a similar Australian dataset, with early 
mobilisation estimated to account for 78% of the beneﬁ t,1 
giving a ﬁ nal absolute diﬀ erence of 7·1%. A sample of 
2104 patients (1052 per group) was estimated to provide 
80% power to detect a signiﬁ cant intervention eﬀ ect 
(two sided, p=0·05) with adjustments for 5% drop-in and 
10% drop-out. We prespeciﬁ ed our statistical analysis 
plan16 and used STATA IC (version 13) for all analyses.
We did primary eﬃ  cacy analysis on an intention-to-treat 
basis, with an assumption for the main analysis that data 
were missing at random.21 We explored the sensitivity of the 
Very early 
mobilisation 
(n=1054)
Usual care 
(n=1050)
Recruitment region
Australia and New Zealand 617 (59%) 626 (60%)
Asia 126 (12%) 125 (12%)
UK 311 (29%) 299 (28%)
Age (years) 72·3 (62·3–80·3) 72·7 (63·4–80·4)
<65 331 (31%) 298 (28%)
65–80 448 (43%) 481 (46%)
>80 275 (26%) 271 (26%)
Sex
Female 411 (39%) 407 (39%)
Male 643 (61%) 643 (61%)
Risk factors
Hypertension 707 (67%) 717 (68%)
Ischaemic heart disease 235 (22%) 251 (24%)
Hypercholesterolaemia 419 (40%) 423 (40%)
Diabetes mellitus 239 (23%) 228 (21%)
Smoking
Never smoked 454 (43%) 491 (47%)
Smoker* 227 (22%) 204 (19%)
Ex-smoker* 352 (33%) 341 (33%)
Unknown 21 (2%) 14 (1%)
Atrial ﬁ brillation 229 (22%) 237 (23%)
Premorbid history
Premorbid modiﬁ ed 
Rankin Scale
0 799 (76%) 786 (75%)
1 145 (14%) 158 (15%)
2 110 (10%) 106 (10%)
Living arrangement at 
time of admission
Home alone 257 (25%) 275 (26%)
Home with someone 781 (74%) 761 (73%)
Supported 
accommodation
16 (1%) 14 (1%)
Independent walking
Without aid 908 (86%) 925 (88%)
With aid 146 (14%) 125 (12%)
Time to randomisation (h) 18·2 (12·1–21·8) 18·2 (12·5–21·8)
Stroke history
First stroke 878 (83%) 843 (80%)
NIHSS score 7 (4–12) 7 (4–12)
Mild (1–7) 592 (56%) 578 (55%)
Moderate (8–16) 315 (30%) 328 (31%)
Severe (>16) 147 (14%) 144 (14%)
Stroke type (Oxfordshire 
Stroke Classiﬁ cation)
Total anterior circulation 
infarct
224 (21%) 232 (22%)
Partial anterior 
circulation infarct
340 (32%) 328 (31%)
Posterior circulation 
infarct
93 (9%) 106 (10%)
(Table 1 continues in next column)
Very early 
mobilisation 
(n=1054)
Usual care 
(n=1050)
(Continued from previous column)
Lacunar infarct 255 (24%) 268 (26%)
Intracerebral 
haemorrhage
142 (14%) 116 (11%)
rtPA treatment
Yes 247 (23%) 260 (25%)
Baseline walking (Mobility 
Scale for Acute Stroke 
walking score)
Independent 439 (42%) 416 (40%)
Supervised or assisted 522 (49%) 538 (51%)
Unable to walk 91 (9%) 96 (9%)
Unknown 2 (<1%) 0 (0%)
 Data are n (%) or median (IQR). NIHSS=National Institutes of Health Stroke Scale. 
rtPA=recombinant tissue plasminogen activator. *We deﬁ ned a smoker as a 
current smoker or a participant who had quit smoking in the past 2 years, and an 
ex-smoker as a participant who had quit smoking more than 2 years ago.
Table 1: Baseline characteristics of the intention-to-treat population
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results to plausible departures from the missing-at-random 
assumption as part of our intention-to-treat analysis, with 
use of both a selection model (modelling of the missing 
data mechanism) and a pattern mixture model (modelling 
of the diﬀ erences between missing and observed data). 
Assumptions about the missing data were expressed via a 
parameter that measures the degree of departure from the 
missing-at-random assumption. The results were graphed 
over a range of assumptions (appendix).
We did the primary eﬃ  cacy analysis with the binary 
logistic regression model, with treatment group as an 
independent variable and the 3 month modiﬁ ed Rankin 
Scale outcome (dichotomised into scores of 0–2 as 
favourable outcome, and scores of 3–6 as poor outcome) 
as the dependent variable, including baseline stroke 
Very early mobilisation (n=1054) Usual care (n=1050) p value Median shift (95% CI)
Time to ﬁ rst mobilisation (h) 18·5 (12·8–22·3; n=1042*) 22·4 (16·5–29·3; n=1036*) <0·0001 4·8 (4·1–5·7)
Frequency per person† 6·5 (4·0–9·5) 3 (2·0–4·5) <0·0001 3 (3–3·5)
Daily amount per person (min)‡ 31 (16·5–50·5) 10 (0–18) <0·0001 21·0 (20–22·5)
Total amount per person (min)§ 201·5 (108–340) 70 (32–130) <0·0001 117 (107–128)
Data are median (IQR) or median (IQR; n), unless otherwise indicated. Dose data for very early mobilisation includes components of both usual care and very early 
mobilisation. Frequency is derived from nursing and therapist data. Amount (min) is derived from physiotherapist data only. Median estimates include days when time or 
number of out-of-bed sessions were zero—ie, the patient was recorded as not getting up on that day or for that session. *12 patients were missing from the very early 
mobilisation group and 14 patients were missing from the usual care group. Missing patients were never mobilised, either because of an early serious adverse event, 
decision to palliate, or early death or transfer from the stroke unit. For these patients, therapy and nurse recording forms were completed throughout their stroke-unit stay, 
with zero time and zero sessions. †Daily sessions of out-of-bed activity. ‡Min per day spent in out-of-bed activity. §Total amount is over the length of stay or until 14 days 
after stroke (whichever took place ﬁ rst).
Table 2: Intervention summary
Very early 
mobilisation 
(n=1038*)
Usual care 
(n=1045*)
Adjusted analysis Unadjusted analysis
OR, generalised OR, 
or HR† (95% CI)
p value OR generalised OR, 
or HR† (95% CI)
p value
Primary
Favourable outcome‡ 480 (46%) 525 (50%) 0·73 (0·59–0·90) 0·004 0·85 (0·72–1·0) 0·068
Secondary
mRS category ·· ·· 0·94 (0·85–1·03) 0·193 0·94 (0·85–1·03) 0·202
0 90 (9%) 96 (9%) ·· ·· ·· ··
1 200 (19%) 204 (19%) ·· ·· ·· ··
2 190 (18%) 225 (22%) ·· ·· ·· ··
3 238 (23%) 218 (21%) ·· ·· ·· ··
4 140 (14%) 127 (12%) ·· ·· ·· ··
5 92 (9%) 103 (10%) ·· ·· ·· ··
6 88 (8%) 72 (7%) ·· ·· ·· ··
Walking 50 m unassisted§ 6 (5–7; n=1051) 7 (6–8; n=1049) 1·04 (0·94–1·15) 0·459 1·05 (0·95–1·16) 0·331
 Data are n (%) or median (IQR; n), unless otherwise indicated. All analyses are adjusted for baseline National Institutes of Health Stroke Scale score and age. OR=odds ratio. 
HR=hazard ratio. mRS=modiﬁ ed Rankin Scale. *16 patients were missing from the very early mobilisation group and ﬁ ve patients were missing from the usual care group. 
These 21 patients declined follow-up or could not be found. Missing data were analysed according to our intention-to-treat strategy assuming missing at random. The 
appendix shows results of the sensitivity analysis. †Point estimates are ORs for the primary outcome, generalised ORs for the secondary outcome of mRS category, and HRs 
for the secondary outcome of walking unassisted. ‡mRS 0–2. §Time at which 50% of participants walked. The number walking unassisted includes all patients who were 
recorded as having walked 50 m unassisted in the ﬁ rst 3 months. This number might include patients for whom we were unable to obtain 3 month mRS.
Table 3: Outcomes at 3 months
Figure 2: Patients achieving each mRS score at 3 months
mRS=modiﬁ ed Rankin Scale.
No symptoms Death
9
9
19
19
22
18
21
23
12
14
10
9
7
8
0 20 40 60 80 100
Usual care
Very early
mobilisation
Proportion (%)
mRS=0 mRS=1 mRS=2 mRS=3 mRS=4 mRS=5 mRS=6
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severity (NIHSS) and age as treatment covariates for 
adjustment purposes.
Additional eﬃ  cacy analyses of primary outcome included 
exploratory analyses of age (<65; 65–79; >80); stroke 
severity (mild: NIHSS<7; moderate: 8–16; and severe: >16); 
stroke type (ischaemic vs haemorrhagic); treatment with 
recombinant tissue plasminogen activator; time to ﬁ rst 
mobilisation (<12 h; 12–24 h; >24 h); and geographical 
region (Australia and New Zealand vs Asia vs UK), with 
adjustment for age and stroke severity when relevant.
We estimated the treatment eﬀ ect for ordinal analysis 
of the modiﬁ ed Rankin Scale (across the full scale) at 
3 months with the assumption-free Wilcoxon-Mann-
Whitney generalised odds ratio approach,19,20 providing a 
measure of eﬀ ect size with conﬁ dence intervals. The 
analysis was again stratiﬁ ed by age and stroke severity.
To examine time taken to achieve unassisted walking 
50 m within the ﬁ rst 3 months of stroke, we used a 
Cox regression model with treatment group as the 
independent variable, the time to unassisted walking 
(censored at 3 months) as the dependent variable, and 
baseline NIHSS and age as treatment covariates. We 
present the estimated eﬀ ect size as a hazard ratio (HR) 
with corresponding 95% CI. We analysed walking status 
(yes or no) with a binary logistic model, with treatment 
group as the independent variable and walking status as 
the dependent variable.
We analysed mortality outcomes with the binary 
logistic regression model, with treatment group as the 
independent variable and death at 3 months (modiﬁ ed 
Rankin Scale score of 6) as the dependent variable, and 
stroke severity and age as treatment covariates. We used 
negative binomial regression to compare the expected 
counts of serious complications between groups at 
3 months. We report the estimated eﬀ ect sizes and 
corresponding 95% CI as incidence rate ratios adjusted 
for age and stroke severity.
To determine whether practice shifted over the course 
of this trial, we tested the association between the 
treatment eﬀ ect and the time since the beginning of the 
trial by inclusion of an appropriate interaction term into 
the logistic regression model used for the primary 
outcome analysis. To further examine the possible 
eﬀ ects of time on the intervention delivered, we did an 
exploratory analysis in which we examined the eﬀ ect of 
time since the beginning of the trial on diﬀ erences in 
individual dose characteristics between the two groups 
with appropriate regression models (ie, a median 
regression model for time to ﬁ rst mobilisation and 
median session frequency, and negative binomial 
regression for median daily minutes per session and 
total min over the intervention period) with an 
interaction term for treatment by time since the trial 
began.
This trial was registered with the Australian New Zealand 
Clinical Trials Registry, number ACTRN12606000185561 
and the protocol is available online.
Figure 3: Time to walking unassisted 50 m by 3 months
*Number of patients who had not achieved walking. 
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p=0·459
Very early 
mobilisation 
(n=1054)
Usual care 
(n=1050)
OR or IRR* (95% CI) p value
Death 88/1048 (8%)† 72 (7%) 1·34 (0·93–1·93) 0·113
Non-fatal serious adverse events 0·88 (0·72–1·07) 0·194
0 853 (81%) 842 (80%) ·· ··
1 157 (15%) 146 (14%) ·· ··
2 32 (3%) 41 (4%) ·· ··
3 10 (1%) 16 (2%) ·· ··
4 2 (<1%) 4 (<1%) ·· ··
5 0 1 (<1%) ·· ··
Immobility serious adverse 
events‡
0·92 (0·62–1·35) 0·665
0 1000 (95%) 997 (95%) ·· ··
1 50 (5%) 46 (4%) ·· ··
2 4 (<1%) 5 (1%) ·· ··
3 0 2 (<1%) ·· ··
4 0 0 ·· ··
5 0 0 ·· ··
Neurological serious adverse 
events‡
1·26 (0·95–1·66) 0·108
0 947 (90%) 967 (92%) ·· ··
1 104 (10%) 78 (7%) ·· ··
2 3 (<1%) 4 (<1%) ·· ··
3 0 1 (<1%) ·· ··
4 0 0 ·· ··
Data are n/N (%) or n (%), unless otherwise indicated. We did IRR analysis with event counts per person. All 
analyses are adjusted for age and baseline National Institutes of Health Stroke Scale score. OR=odds ratio. 
IRR=incidence rate ratio. *Point estimates are OR for death and IRRs for all adverse events. †The 3 month outcome 
was missing (unknown) for six patients in the very early mobilisation group. Missing data were analysed 
according to our intention-to-treat strategy assuming missing at random. The results remain stable over the 
range of possible violations of this assumption. ‡Immobility-related and neurological serious adverse events 
include both fatal and non-fatal complications; immobility-related events include pulmonary embolism, 
deep-vein thrombosis, urinary tract infection, pressure sores, pneumonia; and neurological events include stroke 
progression and recurrent stroke.
Table 4: Deaths and serious complications at 3 months
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Role of the funding source
The funders of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. The corresponding author had full 
access to all the data in the study and, with support of the 
management committee, had ﬁ nal responsibility for the 
decision to submit for publication.
Results
Figure 1 shows the trial proﬁ le. Between July 18, 2006, 
and Oct 16, 2014, we randomly assigned 2104 patients to 
receive either very early mobilisation (n=1054) or usual 
care (n=1050), with 2083 (99%) patients included in the 
3 month follow-up assessment (ﬁ gure 1). Baseline 
characteristics were similar between study groups 
(table 1). Median time to randomisation was 18 h after 
stroke in both groups (table 1). For more than 80% of 
patients, this stroke was their ﬁ rst; 45% of patients were 
classiﬁ ed as having moderate to severe stroke (NIHSS 
>7) at time of recruitment, 26% of all patients were older 
than 80 years, and 24% of patients had received 
recombinant tissue plasminogen activator (table 1).
The three crucial elements of the very early mobilisation 
protocol were achieved (table 2). Patients in the very early 
mobilisation group began mobilising soon after 
randomisation, at a median of 18·5 h after stroke 
(table 2). The median time to mobilisation in the usual 
care group was also within 24 h of stroke onset, but the 
median diﬀ erence was almost 5 h later than in patients 
in the very early mobilisation group (table 2). In the very 
early mobilisation group, 241 (23%) patients had 
mobilised within 12 h of stroke, 965 (92%) patients 
had mobilised within 24 h, and 1038 (98%) patients had 
mobilised within 48 h; the corresponding numbers in the 
usual care group were 148 (14%), 623 (59%), and 
977 (93%) patients, respectively. Patients in the very early 
mobilisation group received more frequent out-of-bed 
sessions than did those in the usual care group (table 2). 
The median time to ﬁ rst mobilisation in the usual care 
group reduced by 28 min per year (95% CI 11·3–44·6, 
p=0·001) over the study period, with no signiﬁ cant 
change in the very early mobilisation group. This ﬁ nding 
resulted in a signiﬁ cant interaction between time since 
the beginning of the trial and time to ﬁ rst mobilisation 
(p=0·017). We detected no signiﬁ cant change in either 
the daily frequency or daily minutes of out-of-bed 
intervention, or total intervention time, in either group 
over the study period (data not shown).
More patients in the usual care group than in the very 
early mobilisation group had a favourable outcome at 
3 months after stroke (table 3), resulting in a signiﬁ cant 
diﬀ erence between the groups in the analyses adjusted 
for baseline age and NIHSS (table 3, ﬁ gure 2). We noted 
similar results in sensitivity analyses (appendix). This 
treatment eﬀ ect showed no interaction with time since 
the start of the trial (data not shown). The assumption-
free ordinal analysis did not show a signiﬁ cant diﬀ erence 
between groups across the entire modiﬁ ed Rankin Scale 
(scores 0–6).
50% of patients were able to walk unassisted by roughly 
7 days after stroke, and 75% were walking by 3 months 
(n=796 in the usual care group and n=784 in the very early 
mobilisation group; adjusted OR 0·83, 95% CI 0·64–1·07; 
p=0·143). Time to walking unassisted did not diﬀ er 
signiﬁ cantly between groups (table 3, ﬁ gure 3); however, 
the proportional hazards assumption was violated.
The overall case fatality by 3 months was 8% (95% CI 
6·5–8·8). 72 (7%) patients died in the usual care group 
and 88 (8%) patients died in the very early mobilisation 
group (table 4). The main causes of death, accounting for 
64% of all deaths, were stroke progression (n=19 in the 
usual care group vs n=31 in the very early mobilisation 
group), pneumonia (n=15 vs n=19), and recurrent stroke 
(n=7 vs n=11). Most patients did not have a serious adverse 
event in the ﬁ rst 3 months (table 4). The proportion of 
patients who had non-fatal serious adverse events did not 
diﬀ er signiﬁ cantly between groups (table 4). When 
complications were examined by prespeciﬁ ed category 
(immobility vs neurological), fewer than 6% of patients in 
either group had a fatal or non-fatal serious complication 
related to immobility (table 4). Fewer than 12% of patients 
in either group had a serious neurological complication 
(table 4), with no signiﬁ cant between-group diﬀ erences. 
Figure 4: Prespeciﬁ ed subgroup analyses
None of the individual subgroup analyses had signiﬁ cant treatment-by-
subgroup interactions (all p>0·05). OR=odds ratio. rtPA=recombinant tissue 
plasminogen activator. 
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Stroke progression was the most common serious 
neurological complication, recorded in 128 (6%) patients 
(n=56 in the usual care group vs n=72 in the very early 
mobilisation group). Only one staﬀ  injury was reported in 
the very early mobilisation group.
In the prespeciﬁ ed subgroup analyses we noted a more 
favourable outcome for the usual care intervention than 
for the very early mobilisation intervention (ﬁ gure 4). 
The point estimate showed a stronger eﬀ ect in patients 
with severe stroke and with intracerebral haemorrhage 
(estimated with lower precision). However, within each 
individual subgroup analysis, no signiﬁ cant interactions 
were recorded (all p>0·05; ﬁ gure 4). The appendix shows 
dose characteristics by subgroup and the subgroup 
analysis for death at 3 months. Although the eﬀ ect of 
very early mobilisation on patients with intracerebral 
haemorrhage seemed to be strong, again, no signiﬁ cant 
interactions were recorded in this analysis (all p>0·05; 
appendix).
The median length of hospital stay for acute care and 
rehabilitation was 16 days (IQR 5–44) for patients in the 
very early mobilisation group and 18 days (6–43) for those 
in the usual care group. The number of patients moving 
on to inpatient rehabilitation was 492 (46%) in the very 
early mobilisation group and 523 (49%) in the usual care 
group. Median length of stay for acute care alone was 
7 days (IQR 4–13) for patients receiving very early 
mobilisation and 7 days (4–13) for those receiving usual 
care; the corresponding times for rehabilitation length of 
stay were 28 days (15–49) and 30 days (16–51), respectively.
Discussion
Our very early mobilisation protocol was eﬀ ectively 
delivered, leading to an earlier, more frequent, and higher 
dose of out-of-bed sitting, standing, and walking activity 
than usual care. The very early mobilisation intervention 
signiﬁ cantly reduced the odds of a favourable outcome 
3 months after stroke compared with lower dose usual 
care starting, on average, 5 h later. This outcome of very 
early mobilisation was recorded against a background of 
favourable overall prognosis, with almost 50% of patients 
having a favourable outcome and fewer than 8% dying at 
3 months, despite more than 25% of participants being 
older than 80 years, and more than 45% having had a 
moderate or severe stroke. Although the case-fatality rate 
at 3 months was higher in the very early mobilisation 
group, no signiﬁ cant diﬀ erence was recorded between 
groups. The prespeciﬁ ed subgroup analyses of eﬃ  cacy 
might provide a signal that patients with severe stroke 
and those with intracerebral haemorrhage had reduced 
odds of a favourable outcome by 3 months if treated 
with the very early mobilisation protocol. Additional 
exploration of death in the subgroups also suggested that 
patients with intracerebral haemorrhage might be more 
susceptible to harm. However, these groups were small 
with wide conﬁ dence intervals. Although biologically 
plausible explanations could be made about the 
diﬀ erential eﬀ ect of a more frequent, higher dose 
intervention on the odds of a favourable or unfavourable 
outcome in these subgroups, there was no evidence of 
any interaction and the results should be interpreted with 
caution. This study was not powered to detect diﬀ erences 
between these subgroups; however, such signals of 
potential harm could be clinically important and warrant 
further exploration. We also noted that outcomes for 
patients receiving recombinant tissue plasminogen 
activator were no diﬀ erent to outcomes for those who did 
not receive that treatment. Hence, there is no evidence 
that early mobilisation in this subgroup is harmful.
We were intrigued by these results, partly because our 
pilot work suggested that the early, frequent, higher dose 
very early mobilisation protocol increased the odds of 
a favourable outcome (OR 4·1, 95% CI 0·99–16·89; 
p=0·05),12 as did an individual patient meta-analysis, 
which included two small early mobilisation trials.22 
Conversely, another small trial comparing very early 
(<24 h) versus later (>24 h) mobilisation, with an 
unspeciﬁ ed training dose, reported higher, but non-
signiﬁ cant odds, of an unfavourable outcome in the 
earlier mobilised group.23 Because the AVERT trial is 
more than ten times the size of the total sample of all 
previous mobilisation trials, we believe that our results 
add precision. The low rates of adverse events overall 
and, in particular, the low proportion of immobility-
related complications in both groups was surprising. 
Our clinical hypothesis was that very early mobilisation 
would lead to fewer immobility-related complications, 
but we noted no diﬀ erence between groups. The shift in 
practice over time to earlier onset intervention in usual 
care (a median 28 min earlier each year) might explain 
this result. One of the striking diﬀ erences between 
previous studies and the present trial is that median 
time to ﬁ rst mobilisation in usual care has decreased 
from more than 30 h,22 to 22 h in this trial. Only 7% of 
patients in our usual care group stayed in bed for more 
than 48 h after stroke onset. Unfortunately, no directly 
comparable data are available from other acute stroke 
trials. AVERT is the ﬁ rst large rehabilitation trial 
recruiting patients within 24 h of stroke onset, and 
although the inclusion criteria were broad, the included 
patients were a selected population. Modern, high 
quality stroke-unit care in the participating hospitals, 
which did include out-of-bed mobilisation within 24 h of 
stroke onset in 75% of cases, could explain the low rate 
of immobility-related complications.
This study represents the largest acute stroke 
rehabilitation trial ever done with a complex intervention 
directed by existing physiotherapy and nursing staﬀ . We 
aimed to design and undertake a trial that met the same 
quality standards expected of drug or device trials, so that 
eﬀ ect sizes could be sensibly compared. We have achieved 
this aim, with fewer than 1% of patients missing from the 
primary endpoint calculation, proven delivery of the 
intervention protocol, careful characterisation of usual 
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care and adjudicated safety outcomes, and provision of 
precise estimates of the eﬃ  cacy and safety of the 
intervention. The external validity of the trial has been 
enhanced by embedding it fully within routine hospital 
care across ﬁ ve countries. In view of these design 
considerations, we believe that these results are robust 
and provide clinicians with important new evidence.
Our trial has several limitations. A consequence of 
doing large trials is the small amount of information that 
can be obtained about potential confounding factors 
(such as physiological variables), and about each staﬀ –
patient interaction. This limitation will restrict, but not 
prevent, further detailed analyses of the eﬀ ect of patient 
and practice variables on outcome. Being a pragmatic 
trial, we were not prescriptive about usual care 
mobilisation practices, which changed signiﬁ cantly 
during the trial. Independent monitoring, reporting, and 
feedback about usual care and very early mobilisation did 
not prevent change in usual care. Usual care clinicians 
started mobilisation earlier each year, with the result that 
roughly 60% of patients receiving usual care had started 
out-of-bed therapy within 24 h of stroke onset. Whether 
this result was a consequence of contamination from the 
trial protocol, a response to changes in attitudes to early 
mobilisation over time as reﬂ ected in recent clinical 
guidelines, or both, is uncertain.
The results of our trial should aﬀ ect clinical practice by 
changing present clinical practice guidelines. In our 
review of 30 guidelines, early mobilisation was 
recommended in 22 examples,3 but with little, or more 
often no, information about the protocol that should be 
used. The obvious implication of our results is that start 
of a high-dose, frequent mobilisation protocol within 24 h 
of stroke onset is not better than usual care. However, 
because the usual care protocol also represents a complex 
intervention package that in most cases started early, to 
advise that patients are provided with usual care is too 
simplistic. Components of our intervention are already 
part of routine clinical care; therefore, understanding of 
which components might aﬀ ect outcome is a priority. By 
further exploration of this rich dataset, our trial provides 
the best opportunity yet to develop evidence-based 
guidelines for patients with stroke about the timing, 
frequency, and amount of out-of-bed activity to improve 
outcome (or prevent harm). Consequently, as outlined in 
our published statistical analysis plan,16 our next priority 
will be to undertake a dose–response analysis to establish 
the eﬀ ect of dose of rehabilitation (rather than group) on 
eﬃ  cacy and safety outcomes.
The results of AVERT raise several important research 
questions. First, when is the best time to start 
rehabilitation after stroke? Whereas some early studies in 
stroke-aﬀ ected rodents suggested that early, intensive 
exercise increased lesion volume, more recent systematic 
reviews and meta-analyses have shown a strong positive 
eﬀ ect for exercise after stroke, including a positive 
association between better outcome and reduced time to 
starting exercise.24,25 An improved understanding is 
needed of the molecular mechanisms induced by early 
physical activity on ischaemic tissue to provide a biological 
rationale for choice of time windows for intervention. 
Indeed, this question remains one of the most important 
questions for the entire timescale after stroke. Second, 
what should training consist of, and who should we target 
early? We have shown that the common adage of more is 
better does not apply to the early post-stroke period. 
Furthermore, our data signal that some patients might 
respond better to more conservative treatment protocols. 
A deep understanding of who responds to treatment, who 
does not, and why, is missing in the specialty of 
rehabilitation and should be a research priority.
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